To clarify, I believe the time frame CEO Leo referred to is for the initial Top-Line data.
The final full clinical study result, aka Bottom-Line data would come after. It would not surprise me to see it published in a peer reviewed journal.
For our purposes, the Top-Line data is the big catalyst.
I agree the verbiage Leo used suggests late October to early November. I'm guessing he's also being conservative in that guidance, allowing for time for the data to be delivered and analyzed. Both could come quicker as it's not a complicated trial.